Teladoc Health (NYSE:TDOC – Get Free Report) updated its third quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of -0.300–0.200 for the period, compared to the consensus EPS estimate of -0.170. The company issued revenue guidance of $569.0 million-$609.0 million, compared to the consensus revenue estimate of $629.1 million. Teladoc Health also updated its FY 2026 guidance to -1.000–0.750 EPS.
Analysts Set New Price Targets
Several equities research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group cut their price target on shares of Teladoc Health from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Thursday. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, Bank of America upped their price objective on shares of Teladoc Health from $9.00 to $10.50 and gave the company a “buy” rating in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $7.50.
Get Our Latest Analysis on TDOC
Teladoc Health Stock Down 29.2%
Teladoc Health (NYSE:TDOC – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The firm had revenue of $606.93 million during the quarter, compared to analyst estimates of $615.44 million. During the same period in the previous year, the company posted ($0.19) EPS. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. On average, research analysts forecast that Teladoc Health will post -0.92 earnings per share for the current year.
Insider Activity
In other news, insider Adam C. Vandervoort sold 7,906 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $60,322.78. Following the completion of the sale, the insider owned 110,261 shares in the company, valued at $841,291.43. This represents a 6.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Carlos Nueno sold 6,196 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $47,275.48. Following the completion of the sale, the insider owned 57,671 shares of the company’s stock, valued at approximately $440,029.73. This represents a 9.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 39,195 shares of company stock valued at $299,058 over the last quarter. 0.70% of the stock is owned by insiders.
Trending Headlines about Teladoc Health
Here are the key news stories impacting Teladoc Health this week:
- Positive Sentiment: Teladoc reported a second-quarter adjusted loss of $0.21 per share, better than the $0.24 consensus estimate. Management also highlighted efficiency efforts, while operating cash flow totaled $64.7 million. Teladoc Health Reports Second Quarter 2026 Results
- Positive Sentiment: Canaccord Genuity lowered its price target from $11 to $10 but retained a “buy” rating, implying substantial potential upside from recent levels. Benzinga analyst price target report
- Positive Sentiment: Unusually heavy call-option activity—15,650 contracts, about 30% above average—suggests some traders are positioning for a rebound, although options flows can be speculative and volatile.
- Neutral Sentiment: The second-quarter net loss was $38.9 million, or $0.21 per share, compared with a $0.19 loss a year earlier. However, first-half cost controls narrowed the net loss even as sales remained under pressure. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
- Negative Sentiment: Revenue fell 4% year over year to $606.9 million, missing estimates of roughly $615.4 million. The company also cited shifting demand for BetterHelp, its mental-health unit, as a major pressure on results. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
- Negative Sentiment: Teladoc reduced its full-year 2026 revenue outlook to approximately $2.4 billion, below the $2.5 billion consensus. Third-quarter revenue guidance of $569 million to $609 million also fell well short of the roughly $629 million analyst estimate, while the projected quarterly loss is wider than expected. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook
Hedge Funds Weigh In On Teladoc Health
Several large investors have recently modified their holdings of TDOC. Entropy Technologies LP bought a new position in Teladoc Health in the 3rd quarter worth approximately $133,000. Polymer Capital Management US LLC bought a new position in shares of Teladoc Health in the third quarter worth $131,000. HighTower Advisors LLC grew its position in shares of Teladoc Health by 19.2% in the fourth quarter. HighTower Advisors LLC now owns 18,647 shares of the health services provider’s stock valued at $131,000 after purchasing an additional 2,997 shares in the last quarter. Martingale Asset Management L P bought a new stake in shares of Teladoc Health during the 4th quarter valued at $116,000. Finally, Manhattan West Asset Management LLC bought a new stake in shares of Teladoc Health during the 2nd quarter valued at $100,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.
Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.
Read More
- Five stocks we like better than Teladoc Health
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.
